A RADIOPHARM FORMATION PROCESS WITH LEUKOCYTES AND / OR TRUNK CELLS, ASSOCIATED WITH INFLAMMATORY AND / OR INFECTIOUS PROCESSES, AND CELLULAR THERAPY, RESPECTIVELY； IN VIVO DIAGNOSTIC METHODS OF INFLAMMATORY AND / OR INFECTIOUS PROCESSES USING MARKED LEUKOCYTES； AND ACCOMPANYING CELL THERAPY USING MARKED BONE CELLS； KIT FOR MARKING OF LEUKOCYTES FOR DIAGNOSIS OF INFLAMMATORY AND / OR INFECTIOUS PROCESSES AND KIT FOR MARKING OF CELLSTRONCO FOR IN VIVO MONITORING OF CELL THERAPY
Process of formation of radiopharmaceutical with leukocytes and /or stem cells associated with inflammatory and /or infectious processes and cell therapy respectively； in vivo diagnostic methods of inflammatory and /or infectious processes using marked leukocytes； and monitoring of Cell therapy using marked stem cells； a leucocyte -marking kit for the diagnosis of inflammatory and /or infectious processes and a screening kit for in vivo cell therapy for the present application for a patent patent for invention privilege,Is characterised primarily by a process of formation of radiopharmaceuticals with leukocytes and /or cells associated with inflammatory and /or infectious processes and cell therapy respectively； in vivo diagnostic methods of inflammatory and /or infectious processes using leukaemia Marked cells； and follow -up cell therapy using marker cell cells； leucocyte Marking Kit for the diagnosis of inflammatory and /or infectious processes and stem cell marking kit for in vivo cell therapy monitoring, the function of which is And aiming at early evaluation,Monitoring and differentiation of infectious and /or inflammatory processes with regard to marker leukocytes； and monitoring of cell therapy using marked stem cells. A simple method has been developed for the formation of leukocytes and /or stem cells with radiopharmaceuticals, particularly technetium -99m, which provides high -efficiency training, and does not alter cell integrity at low cost and lower blood volume for the performance Training compared to other techniques already described. The formation of leukocytes and /or stem cells with radiopharmaceutical, in particular technetium -99m, uses a reducing agent,In particular stannous chloride. Marked cells are used for later in vitro or in vivo application in the evaluation of inflammatory and /or infectious processes and in vivo monitoring of cell therapy.processo de formação de radiofármaco com leucócitos e/ou células-tronco, associados a processos i
